Regeneron; and serving as a consultant/advisory board member for AstraZeneca, BMS, Debiopharm, Nanobiotix, and Tilos. G.J.H. reports research support to institution from BMS and EMD Serono. R.B.T. reports serving on the data safety monitoring board for Intrexon/PSI and on the advisory board for EMD Serono and Regeneron. N.G.C. reports research funding from Merck, Pfizer, and GlaxoSmithKline. G.R. reports consulting for EMD Serono, Pfizer, Merck, Regeneron, Sanofi, and Castle; and owning stocks in Regeneron and Syros pharmaceuticals.
Pancreatic cancer is one of the most devastating forms of human cancer. The lack of effective clinical treatments for pancreatic cancer has led to one of the lowest five-year survival rates among all cancers. Recently, our laboratory has developed a novel series of isoprenylated coumarin derivatives that have exhibited anti-pancreatic cancer activity exclusively under nutrient-deprived conditions. In this study, we report the effect of the various cell culture medium components on the preferential cytotoxicity of our lead isoprenylated coumarin compound against the pancreatic adenocarcinoma cell line PANC-1. In particular, our findings show a clear link between observed cytotoxicity and glucose deprivation, suggesting that our compound targets a salvage pathway when glycolysis is no longer an option for cancer cell survival. The cytotoxicity of our lead compound was also examined in vitro against two other pancreatic cancer cell lines, BxPC-3 and Capan-2 under both nutrient-rich and nutrient-deprived conditions.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.